Peptides for Immune SupportThe Complete Protocol Guide

Your immune system is not a single switch. It is layered architecture — cellular energy, antioxidant capacity, inflammatory regulation, T-cell production, mucosal barriers — and each layer degrades differently with age and illness. The conventional answer to immune decline is vitamin C and zinc. The peptide community's answer is often "just take thymosin alpha-1." Both miss the structure.

A single compound cannot restore a system that fails across multiple layers simultaneously. This protocol sequences six compounds across four phases — NAD+, Selank, glutathione, KPV, thymosin alpha-1, and thymulin — building from metabolic foundation through inflammatory calming to immune reconstitution.

The evidence behind each compound varies, and that variation matters. Thymosin alpha-1 is approved in 35+ countries with randomized controlled trials in hepatitis, sepsis, HIV, and cancer. KPV has no human data at all. NAD+ precursors reduce inflammatory markers in human studies but have no immune-specific RCTs.

The phased sequencing is practitioner-derived and has not been tested in a clinical trial, but it follows from the biology — each ordering decision is rooted in documented immune cell requirements.

Jump to protocol →

At a Glance

Why Your Immune System Declines With Age

Immune decline has a specific origin: the thymus. This small organ behind the sternum is where T-cells learn to distinguish self from threat — and it is the earliest organ to age in the human body. Thymic tissue declines roughly 3% per year from age one, accelerating until less than 5% of original functional tissue remains by late life¹.

As functional tissue disappears, the immune system compensates by cloning existing memory cells instead of producing fresh ones². The result: a system locked into past threats, unable to respond to new ones — why older adults respond poorly to novel infections and vaccines. A supply problem, not a signaling problem.

The paradox: this same decline also weakens the thymus's quality-control process, letting more self-attacking immune cells escape into circulation while regulatory cells that suppress them also drop³. You lose pathogen defense and self-tolerance at the same time.

Aging compounds the damage. Damaged cells accumulate and leak inflammatory signals⁴ that ramp up an enzyme consuming NAD+⁵. Inflammation depletes NAD+, which impairs the regulators that keep inflammation in check, which promotes more inflammation. Effective immune support addresses this layered degradation in sequence.

Phase 1: Build the Foundation

Without metabolic fuel, immune-stimulating peptides have nothing to work with. Phase 1 restores three foundations: NAD+ for cellular energy, Selank for cortisol normalization, glutathione for antioxidant capacity.

Timeline: Weeks 1-4.

NAD+: The Cellular Energy Substrate

Chronic inflammation burns through NAD+ — the energy currency your immune cells run on — by driving up the enzyme that consumes it⁵. When NAD+ drops, immune cells malfunction in two directions: the cells that should be repairing tissue switch to attack mode instead⁶, and the cells that fight infections and tumors slowly stop working⁷.

NR supplementation pulls immune cells back from this exhausted state⁸. In humans, oral NR (1g/day, 3 weeks) reduced inflammatory markers in older men⁹. A 386-person RCT of nicotinamide (500mg BID, 12 months) reduced non-melanoma skin cancer 23%, with increased immune cell infiltration¹⁰. Early signals — no large immune-specific trials yet — but the mechanistic chain is consistent across independent labs.

Dosing: 50–250 mg IM 1–3×/week. Oral alternative: NMN 300–600 mg daily. For route comparison and detailed protocols, see the NAD+ guide.

Selank: The Cortisol-Immune Bridge

Chronic stress suppresses the very immune signals this protocol is trying to restore¹¹. Running immune reconstitution under high cortisol fights the protocol.

Selank is derived from tuftsin, a natural immune-regulating molecule — giving it direct immune properties beyond anxiety reduction. In anxiety disorder patients, it reduced key inflammatory markers while normalizing immune balance¹².

It restores the brain's natural calming circuitry through a different mechanism than benzodiazepines¹³ — no sedation, no tolerance, no dependency. Russian RCTs show anxiety relief comparable to benzodiazepines, with cognitive enhancement on top¹⁴.

For detailed dosing, see the Selank guide.

Dosing: 250–500 mcg SC, 1–2× daily. Intranasal alternative: same dose range.

Glutathione: The Antioxidant Infrastructure

Your immune cells' natural killing power depends on glutathione right now — not after Phase 3. In a small pilot, liposomal glutathione (500-1000 mg/day) elevated natural killer cell activity up to 400% within two weeks¹⁵. An independent RCT (1000 mg/day, 6 months) confirmed >2x natural killer cell increase versus placebo¹⁶.

Glutathione recycling depends on NAD+. When NAD+ is depleted, the body cannot regenerate spent glutathione — so immune cells lose antioxidant protection just as they need it most¹⁷. This is why Phase 1 restores both together.

Dosing: 200–600 mg IM 2–3×/week. Oral alternative: 500 mg liposomal daily.

Phase 2: Calm the Inflammation

Ramping up immune cell production in a body that is already inflamed risks making things worse — the new cells amplify the existing fire instead of fighting threats. Phase 2 calms inflammation so Phase 3 can work cleanly.

Timeline: Weeks 2-6 (overlapping with late Phase 1).

KPV: Precision Mucosal Calming

KPV is a tripeptide fragment of alpha-MSH, one of the body's own inflammation-regulating hormones. It enters inflamed gut tissue through a transporter that gets upregulated wherever inflammation is worst¹⁸ — so it naturally concentrates where it's needed most. Inside the cell, it blocks the master inflammatory switch (NF-kB) by physically competing with it for access to the nucleus¹⁹. At tiny concentrations, it suppresses multiple inflammatory pathways and stabilizes the immune cells (mast cells) responsible for allergic and histamine reactions²⁰.

Evidence caveat: No human clinical trials. All data comes from lab and animal studies²¹. User reports describe IBS, MCAS, and food sensitivity resolution within 2-4 weeks²², but these are anecdotal.

Dosing: 250–500 mcg SC daily. Oral alternative preferred for gut-targeted effects. Start at the lower end. Community protocols favor divided microdosing (50–125 mcg multiple times daily) over single doses.

Regulatory note: The FDA classified KPV as Category 2 ("Substance with Safety Concerns") in 2024, citing zero published human exposure data. This regulatory status reflects the absence of human safety data — not the presence of demonstrated harm. Reclassification petitions are ongoing but unresolved as of March 2026.

VIP: The Tolerance Orchestrator (Optional)

VIP doesn't just reduce inflammation — it teaches the immune system to stop overreacting. It reprograms the cells that coordinate immune responses (dendritic cells) into a calming mode: less attack signaling, more anti-inflammatory output, and the ability to generate the regulatory cells that keep autoimmunity in check²³.

The effect depends on timing — resting immune cells get calmed down, while cells already in attack mode get redirected toward tolerance²⁴. When this tolerance pathway is knocked out in mice, autoimmune disease gets dramatically worse²⁵. VIP also reshapes gut bacteria and dials down the immune system's baseline alarm sensitivity²⁶.

VIP is optional because it carries the most logistical complexity. The Shoemaker CIRS protocol — used in 10,000+ patients — positions it as step 12 of 12, requiring pre/post labs and monthly lipase monitoring²⁷.

Dosing: 50–200 µg SC daily, titrated to response. Nasal spray alternative: 50 µg 4× daily. First dose ideally in a clinical setting.

Phase 3: Rebuild Immune Intelligence

Thymosin alpha-1 is the centerpiece of immune reconstitution — originally isolated from thymus tissue, now synthetically produced and approved in over 35 countries for hepatitis B/C and as an immune enhancer. No other compound in this protocol approaches this level of clinical validation.

Timeline: Weeks 4-8.

Mechanism: How TA1 Restores Immune Intelligence

TA1 works by activating dendritic cells — the instructor cells that train the rest of the immune system — through their threat-detection receptors²⁸. This kicks off a cascade: stronger antiviral and antitumor output, better T-cell maturation, and natural killer cell activation.

The distinction that matters: TA1 doesn't just crank up immune activity. It also strengthens the cells that prevent your immune system from attacking your own tissues²⁹. This is why it helps in both directions: weak immunity (HIV, hepatitis) and overactive immunity (autoimmune conditions, sepsis). In COVID-19 patients with depleted T-cells, TA1 pulled failing cells back into working condition³⁰.

Clinical Evidence

TA1 has decades of human data across viral, cancer, and critical care settings — hepatitis B/C meta-analyses showing combination superiority over interferon alone³¹, HIV studies showing the thymus producing new immune cells again³², and cancer trials where it reduced the immune suppression caused by chemotherapy³⁴.

The largest trial — TESTS, a 1,106-patient sepsis RCT published in the BMJ — found no overall mortality benefit (HR 0.99)³³. But the subgroup data is instructive: patients over 60 and diabetic patients showed meaningful benefit. The populations where thymic decline is most severe are the ones where TA1 works best.

Glutathione Bolstering: Why Phase 3 Demands More

When TA1 drives T-cell expansion, dividing cells must switch from slow, efficient energy production to rapid fuel-burning — and that metabolic shift requires glutathione. Without it, immune cells can activate (the initial signal works) but cannot actually multiply³⁵.

The oxidative balance also has to be precise: too much or too little free radical activity both block the expansion³⁶. Glutathione keeps the window open.

If depletion is lab-confirmed, start at the higher dose in Phase 1.

Dosing: TA1 at 1.6 mg SC daily for 4 weeks. Glutathione increased to 1000 mg daily.

Phase 4: Deepen and Consolidate

Phase 3 used a synthetic drug to rebuild immune cells. Phase 4 adds what the thymus itself produces — thymulin, the gland's own hormone for coordinating immune development. It only works when bound to zinc³⁷, and its levels drop with age as the thymus shrinks. It calms inflammation through a zinc-dependent pathway³⁸.

Timeline: Weeks 9–12.

The evidence is thin. A 1982 Lancet trial showed synthetic thymulin improved immune function in immunodeficient children³⁹. Prasad's 1988 study confirmed that even mild zinc deficiency reduced thymulin activity and immune cell function — all corrected when zinc was restored⁴⁰. These remain the only human interventional data. No modern trials exist. Confirm zinc sufficiency (15-30 mg daily with copper balance) before adding thymulin.

Thymulin vs Thymalin: Different Molecules

This distinction matters because search queries conflate them. Thymulin (facteur thymique serique/FTS) is a single, defined molecule with known structure and mechanism. Thymalin is a crude extract from calf thymus containing multiple peptides, developed by Khavinson in Russia⁴¹.

Thymalin's geroprotective claims — including lifespan extension and immune normalization — come almost entirely from Khavinson's research group with no independent Western replication. The COVID-19 thymalin trial (n=80, unblinded) reported halved hospital mortality, but Khavinson was co-author at his co-affiliated institution⁴². These are not equivalent molecules and should not be treated interchangeably.

Protocol Timeline: Putting It All Together

The phases overlap intentionally — KPV begins in late Phase 1, TA1 begins as KPV establishes inflammatory control. Clinical context determines exact timing.

Phase 1: Foundation (Weeks 1–4)

Phase 2: Calm (Weeks 2–6)

Phase 3: Reconstitute (Weeks 4–8)

Phase 4: Deepen (Weeks 9–12)

Maintenance (Ongoing)

Safety and Side Effects

TA1 deserves specific mention: the FDA added it to the "should not be compounded" list in late 2023, citing "potential significant safety risks." This affects US compounding pharmacy availability. The clinical safety record — decades of use, approval in dozens of countries — stands in tension with this regulatory position. TA1 remains available through research chemical suppliers and international pharmacies.

FAQ

References

¹ Thymic involution rate — thymus begins involuting at approximately age 1, declining ~3%/year until middle age, then <1%/year; <5% of original cellularity remains by late life: Liang et al., Aging Cell 2022

² TCR repertoire narrowing — reduced naive T-cell output leads to homeostatic expansion of memory T-cells, narrowed TCR diversity, and increased susceptibility to novel pathogens: Thomas et al., Immun Ageing 2020

³ Autoimmunity from impaired negative selection — tissue-restricted antigen expression diminishes in aging mTECs; reduced Treg generation removes brake on self-reactive T-cells: Liang et al., Aging Cell 2022; Thomas et al., Immun Ageing 2020

⁴ SASP and inflammaging — senescence-associated secretory phenotype; damaged cells accumulate with age and secrete pro-inflammatory cytokines, chemokines, and proteases: Chini et al., Front Immunol 2025

⁵ CD38-NAD+ depletion cycle — CD38 expression increases with age on macrophages and endothelial cells, driven by SASP factors; primary driver of age-related NAD+ decline; generates immunosuppressive adenosine: Chini et al., Front Immunol 2025; Dwivedi et al., J Oncol 2021

⁶ SIRT1 macrophage polarization — SIRT1 suppresses NF-kB and AP-1 in macrophages, driving M2 (repair) phenotype; NAD+ depletion inactivates SIRT1, defaulting to M1 (inflammatory): Fonseca et al., Genes 2021

⁷ T-cell exhaustion markers — NAD+ depletion drives upregulation of PD-1, TIM-3, LAG-3, and TOX on CD8+ T-cells; mitochondrial dysfunction central to exhaustion phenotype: Alavi et al., Cancers 2022

⁸ NR anti-exhaustion effect — NR (0.5 mM) reduces PD-1 by 6-19%, TIM-3 by 5-11% on CD8+ T-cells; restores TNF-a and IFN-gamma secretion and tumor killing; mediated by SIRT1/PGC-1a/mitochondrial biogenesis: Xiao et al., Nutrients 2024

⁹ NR cytokine reduction in humans — oral NR 1g/day for 3 weeks reduced IL-2, IL-5, IL-6, TNF-a in older men: Elhassan et al., Cell Rep 2019, cited in Martens et al., eClinicalMedicine 2025

¹⁰ Nicotinamide cancer prevention — 500mg BID for 12 months reduced non-melanoma skin cancer 23% (n=386 RCT) with increased CD4+ and CD8+ TILs: Chen et al., NEJM 2015, cited in Alavi et al., Cancers 2022

¹¹ Cortisol-thymulin suppression — chronic cortisol elevation directly suppresses thymulin levels and NK cell function; stress hormones antagonize thymic hormone activity: Prasad et al., J Clin Invest 1988

¹² Selank cytokine reduction — significant reduction in IL-6, IL-1b, TNF-a; normalization of Th1/Th2 balance in patients with anxiety-asthenic disorders: Uchakina et al., Zh Nevrol Psikhiatr 2008

¹³ Selank GABA gene expression — 45 genes involved in GABAergic neurotransmission significantly altered; r=0.86 correlation with exogenous GABA effects; upregulation of GABA-A receptor subunits: Seredenin et al., Acta Naturae 2016

¹⁴ Selank anxiolytic RCTs — efficacy comparable to medazepam (benzodiazepine) in 62-patient RCT with additional cognitive enhancement; effects persist after treatment cessation; no sedation or dependency: Zozulya et al., Neurosci Behav Physiol 2008; Medvedev et al., 2014

¹⁵ Liposomal GSH NK/lymphocyte enhancement — NK cytotoxicity elevated up to 400%, lymphocyte proliferation up to 60% within 2 weeks (n=12, 500-1000 mg/d liposomal GSH): Sinha et al., Eur J Clin Nutr 2018

¹⁶ Oral GSH NK increase — 1000 mg/day for 6 months; GSH increased 30-35% in erythrocytes, plasma, lymphocytes; NK cytotoxicity >2-fold vs placebo at 3 months (n=54 RCT): Richie et al., Eur J Nutr 2015

¹⁷ NAD-NADPH-GSH recycling chain — glutathione reductase requires NADPH (from pentose phosphate pathway and mitochondrial IDH2) to recycle GSSG to GSH; NAD+ depletion limits NADPH, compounding immune cell oxidative stress: Yue et al., Cell Biosci 2023; Yan et al., Cell Mol Immunol 2022

¹⁸ PepT1 upregulation in inflammation — PepT1 normally in small intestine; upregulated in inflamed colon during IBD; KPV transported via PepT1, concentrating in inflamed tissue: Dalmasso et al., Gastroenterology 2008

¹⁹ KPV importin-alpha3 mechanism — KPV enters nucleus and blocks p65RelA interaction with importin-alpha3 armadillo domain 7-8; receptor-independent NF-kB nuclear import blockade: Land, 2012

²⁰ KPV NF-kB and MAPK inhibition — nanomolar concentrations inhibit NF-kB and MAP kinase (ERK1/2, JNK, p38) inflammatory pathways in intestinal epithelial and immune cells: Dalmasso et al., Gastroenterology 2008

²¹ KPV colitis models — oral KPV reduces DSS- and TNBS-induced colitis in mice with decreased pro-inflammatory cytokines: Dalmasso et al., Gastroenterology 2008

²² KPV user reports — anecdotal community reports of IBS, MCAS, hives, food reaction, and allergy resolution within 2-4 weeks; n=1 families, not generalizable: Diary of Recovery blog, 2024

²³ VIP tolerogenic DCs — VIP generates DCs with low CD40/CD80/CD86, low pro-inflammatory cytokines, high IL-10; these DCs induce CD4+ and CD8+ Tregs with CD28-/CTLA4+ phenotype: Gonzalez-Rey et al., Blood 2006; Chorny et al., J Immunol 2005

²⁴ VPAC receptor switching — VPAC1 constitutive on resting T-cells and monocytes; VPAC2 upregulated on activated T-cells; differential expression creates temporal immune regulation: Tan et al., 2015; Juarranz et al., 2019

²⁵ VPAC2 knockout autoimmunity — VPAC2-deficient mice: exacerbated EAE, increased Th1/Th17, reduced Th2/Treg, strikingly reduced CD4+CD25+FoxP3+ Tregs in lymph nodes, thymus, and CNS: Tan et al., 2015

²⁶ VIP microbiome and TLR effects — VIP deficiency causes significant gut microbiota restructuring; VIP downregulates TLR-2/4 via PU.1 transcription factor inhibition: Bains et al., Front Microbiol 2019; Smalley et al., 2009

²⁷ VIP Shoemaker protocol — VIP positioned as step 12 of 12 in CIRS treatment; requires normal VCS, negative MARCoNS, ERMI < 2; first dose in-office with pre/post TGF-beta1 and C4a; monthly lipase monitoring: Shoemaker, 2013

²⁸ TLR-2/9 agonism — TA1 activates toll-like receptors 2 and 9 on myeloid and dendritic cells; increases IL-2, IL-10, IL-12, IFN-alpha, IFN-gamma; promotes T-cell maturation and NK activation: Dominari et al., World J Virol 2020

²⁹ TA1 immunomodulatory (not immunostimulatory) — TA1 enhances Treg activity, IL-10 production, and immune regulation alongside Th1 activation; bidirectional capacity for immunodeficiency and autoimmunity: Dominari et al., World J Virol 2020; Costantini et al., Front Oncol 2019

³⁰ TA1 in COVID-19 T-cell rescue — patients with CD8+ <400/uL or CD4+ <650/uL gained most benefit; TA1 reversed exhaustion by reducing PD-1 and Tim-3 expression: Liu et al., 2020

³¹ TA1 + IFN-alpha hepatitis — combination superiority: HBeAg loss 45.8% vs 28.0% monotherapy; meta-analysis confirmed: Dominari et al., World J Virol 2020

³² TA1 + HAART thymic output — TA1 dramatically increased sjTREC levels (direct thymic output marker) in HIV patients on HAART: Dominari et al., World J Virol 2020

³³ TESTS trial — n=1106, 22 centers, China; 28-day mortality 23.4% vs 24.1% (HR 0.99, 95% CI 0.77-1.27, P=0.93); subgroup: age >=60 HR 0.81, diabetes HR 0.58 (0.35-0.99): TESTS Trial, BMJ 2025

³⁴ TA1 cancer adjunct — reduced chemotherapy immunosuppression and infections, improved QoL and survival in NSCLC: Dominari et al., World J Virol 2020; Costantini et al., Front Oncol 2019

³⁵ GSH gates T-cell metabolic reprogramming — T-cells without GSH (Gclc-knockout) activate normally but cannot switch to aerobic glycolysis for proliferation; GSH required for calcineurin-NFAT-Myc-mTOR cascade: Mak et al., Immunity 2017

³⁶ GSH ROS window for T-cell signaling — both too-high and too-low ROS block metabolic reprogramming; GSH buffers to optimal window permitting NFAT nuclear localization and Myc expression: Klein Geltink et al., Immunity 2017

³⁷ Thymulin age-related decline — serum thymulin levels decline with age in parallel with thymic involution; requires equimolar zinc for biological activity: Dardenne & Safieh-Garabedian, Ann NYAS 2006

³⁸ Thymulin anti-inflammatory mechanism — cAMP-mediated, NF-kB-dependent via IkB-alpha/pIkB-alpha pathway; zinc synergistically amplifies; reduces IL-1b, TNF-a: Safieh-Garabedian et al., Curr Med Chem 2009

³⁹ Thymulin Lancet trial — synthetic FTS (thymulin) administered to immunodeficient children; improved cellular immunity and IgA production: Bordigoni et al., Lancet 1982

⁴⁰ Zinc-thymulin human study — induced mild zinc deficiency decreased thymulin activity, T4+/T8+ ratio, IL-2 activity; corrected with zinc repletion: Prasad et al., J Clin Invest 1988

⁴¹ Khavinson thymalin — all geroprotective and immune claims from single research group (St. Petersburg Institute); no independent Western replication: Khavinson et al., Biol Bull Rev 2021

⁴² Khavinson COVID thymalin trial — n=80, unblinded, single center; Khavinson co-author at co-affiliated institution; reported halved hospital mortality: Kuznik & Khavinson et al., Adv Gerontol 2021

⁴³ GSH NK cell dependence — Gclc-deficient NK cells: impaired proliferation, defective cytokine production, subverted mTOR/STAT5, inability to control viral infection or tumor metastasis: Grusdat et al., Cell Reports 2026

⁴⁴ TA1 bloodwork user data — n=1 immunocompromised user; WBC 3.6->4.4, lymphocytes 2096->2618, CD4 476->551 after 6 injections over 12 days; benefits receded 2 weeks post-discontinuation: ExcelMale Forum

⁴⁵ TA1 safety profile — well-characterized across 35+ countries and decades of clinical use; minimal adverse effects; injection site reactions most common: Dominari et al., World J Virol 2020